Zymeworks Inc. 8K

Zymeworks reported FDA approval of Ziihera regimens for first-line HER2+ gastroesophageal adenocarcinoma, triggering a $250 million milestone payment and expanding its royalty-based revenue potential.

On August 25, 2026, Zymeworks Inc. announced that its partner Jazz Pharmaceuticals received U.S. Food and Drug Administration approval for two Ziihera (zanidatamab-hrii)-containing regimens, with and without Tevimbra (tislelizumab) plus chemotherapy, for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, triggering a $250 million milestone payment to Zymeworks and reinforcing its strategy of deriving non-dilutive capital and future tiered royalties from partnered assets while it advances its wholly owned pipeline of trispecific T-cell engagers and antibody-drug conjugates.

Filing Facts

CIK

1937653

Ticker

ZYME

Form

8K

Source Type

fda

Accession

0001937653-26-000051

Alert Tier

7